Upfront low-dose ponatinib (15 mg/day) for multi-TKI resistant chronic myeloid leukemia

Ayalew Tefferi

doi:10.1002/hon.2517

Upfront low-dose ponatinib (15 mg/day) for multi-TKI resistant chronic myeloid leukemia

Ayalew Tefferi

Hematology

Research output: Contribution to journal › Letter › peer-review

6 Scopus citations

Original language	English (US)
Pages (from-to)	718-720
Number of pages	3
Journal	Hematological Oncology
Volume	36
Issue number	4
DOIs	https://doi.org/10.1002/hon.2517
State	Published - Oct 2018

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1002/hon.2517

Cite this

@article{c845d712e73f4eb5a9a7ccac04652670,

title = "Upfront low-dose ponatinib (15 mg/day) for multi-TKI resistant chronic myeloid leukemia",

author = "Ayalew Tefferi",

year = "2018",

month = oct,

doi = "10.1002/hon.2517",

language = "English (US)",

volume = "36",

pages = "718--720",

journal = "Hematological Oncology",

issn = "0278-0232",

publisher = "John Wiley and Sons Ltd",

number = "4",

}

TY - JOUR

T1 - Upfront low-dose ponatinib (15 mg/day) for multi-TKI resistant chronic myeloid leukemia

AU - Tefferi, Ayalew

PY - 2018/10

Y1 - 2018/10

UR - http://www.scopus.com/inward/record.url?scp=85054818562&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054818562&partnerID=8YFLogxK

U2 - 10.1002/hon.2517

DO - 10.1002/hon.2517

M3 - Letter

C2 - 29901221

AN - SCOPUS:85054818562

SN - 0278-0232

VL - 36

SP - 718

EP - 720

JO - Hematological Oncology

JF - Hematological Oncology

IS - 4

ER -

Upfront low-dose ponatinib (15 mg/day) for multi-TKI resistant chronic myeloid leukemia

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this